Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Metabolism and Pharmacokinetics of SP-8356, a Novel (1S)-(-)-Verbenone Derivative, in Rats and Dogs and Its Implications in Humans

Authors
Zhou, YuanyuanOh, Mun HwanKim, Yeon JoonKim, Eun-yeongKang, JinhongChung, SungJu, ChungKim, Won-KiLee, Kiho
Issue Date
2-4월-2020
Publisher
MDPI
Keywords
SP-8356; pharmacokinetics; metabolism; bioactivation; conjugation
Citation
MOLECULES, v.25, no.8
Indexed
SCIE
SCOPUS
Journal Title
MOLECULES
Volume
25
Number
8
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/56660
DOI
10.3390/molecules25081775
ISSN
1420-3049
Abstract
(1S,5R)-4-((E)-3,4-dihydroxy-5-methoxystryryl)-6,6-dimethylbicylco[3.1.1]hept-3-en-2-one (SP-8356) is a novel (1S)-(-)-verbenone derivative that is currently in preclinical development for the treatment of ischemic stroke and atherosclerosis. This report aimed at characterization of the metabolism and pharmacokinetic properties of SP-8356. Following intravenous dose in rats and dogs, plasma concentrations of SP-8356 declined rapidly with high clearance (CL) and short half-life; after oral administration in both species, its plasma levels were below the quantitation limit. Fourteen circulating metabolites, formed by mono-oxygenation, demethylation, glucuronidation, catechol O-methylation, sulfation and oxidation (bioactivation) followed by glutathione (GSH) conjugation, were tentatively identified in both species. Urinary excretion of SP-8356 appeared to be minimal in rats, compared to its metabolites. GSH conjugate of SP-8356 was also formed during incubation with rat liver S9 fraction consistent with oxidative bioactivation; this bioactivation was almost completely inhibited by the cofactors for glucuronidation, sulfation and methylation, indicating that it may be abolished by competing metabolic reactions in the body. The human pharmacokinetics of SP-8356 was predicted to be similar to that of the animals based on the current in vitro metabolic stability results. In summary, rapid phase II metabolism appears to be mainly responsible for its suboptimal pharmacokinetics, such as high CL and low oral absorption. Because of competing metabolic reactions, potential safety risks related to SP-8356 bioactivation may be low.
Files in This Item
There are no files associated with this item.
Appears in
Collections
Graduate School > Department of Biomedical Sciences > 1. Journal Articles
College of Pharmacy > Department of Pharmaceutical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Ki ho photo

Lee, Ki ho
약학대학 (약학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE